Skip to main content

Translating Induced Pluripotent Stem Cells From Research to Therapy

The properties of induced pluripotent stem cells (iPSCs) make them a prime candidate for cell therapies due to their flexibility and ability to be differentiated into desired cell types. Moreover, certain protocols have been shown to be able to scale to therapeutic quantities. iPSCs are generated by reprogramming easily obtained somatic cells and can differentiate into any cell type from all three germ layers (ectoderm, mesoderm, and endoderm).

We explored some of the challenges and implications of developing a stem cell therapy that are involved when taking iPSCs from the bench into the clinic alongside Regenerative Medicine Network. This eBook offers insight into the raw materials used for the research and development of cell therapies using iPSCs and features interviews with pioneers of the regenerative medicine space. Contents of our eBook include:

  • An interview with Sean Kevlahan, Senior Director of Cell and Gene Therapy at Bio-Techne: Continuous innovation for manufacturing raw/ancillary materials at scale
  • Raw/ancillary material qualification for stem cell therapy manufacturing
  • Quality control guidelines for clinical-grade human induced pluripotent stem cell lines
  • An interview with Jun Takahashi, M.D., Ph.D, : Preparing for the first human trial of induced pluripotent stem cell-derived cells for Parkinson’s disease
  • An interview with Ross Macdonald, Ph.D, CEO and Managing Director of Cynata Therapeutics Limited: The therapeutic potential of iPSCs

This eBook was created by RegMedNet, in association with Bio-Techne.

Request eBook